司美格鲁肽 (诺和诺德)(Semaglutide (Novo Nordisk)) - 药物靶点：GLP-1R_在研适应症：慢性肾病，脑卒中，心肌梗塞_专利_临床

概要

基本信息

药物类型

合成多肽

别名

Semaglutide、Semaglutide (Genetical Recombination)、Semaglutide (genetical recombination) (JAN)

+ [24]

靶点

GLP-1R

作用方式

激动剂

作用机制

GLP-1R激动剂(胰高血糖素样肽-1激动剂)

治疗领域

内分泌与代谢疾病神经系统疾病心血管疾病+ [7]

在研适应症

非在研适应症

原研机构

在研机构

Gilead Sciences, Inc.Novo Nordisk Pharmaceuticals Pty Ltd.

+ [7]

非在研机构-

权益机构

Novo Nordisk A/S

Merck & Co., Inc.

Sumitomo Pharma Co., Ltd.

最高研发阶段批准上市

首次获批日期

美国 (2017-12-05),

2型糖尿病

最高研发阶段(中国)批准上市

特殊审评优先审评 (美国)、突破性疗法 (中国)

登录后查看时间轴

结构/序列

Sequence Code 50953

来源: *****

关联

494

项与司美格鲁肽 (诺和诺德) 相关的临床试验

NCT07021937

/ Not yet recruiting临床3期IIT

Investigating Brain PLASTICity and GLP-1 Receptor Agonists in the Treatment of Obesity: The PLASTIC Trial

Glucagon-like peptide 1 receptor agonists (GLP-1RA), such as Ozempic and Wegovy, have been rapidly adopted for the treatment of obesity in both youth and adults. However, despite this rapid adoption and the known GLP-1RA mechanism of action for weight loss, which targets brain circuits responsible for appetite and eating behaviors, almost nothing is known about how these drugs affect the brain in youth who are treated for obesity, or how these drugs affect the brain of youth differently from adults. The goal of the current study is to compare youth and adults with obesity who are treated a GLP-1RA and measure potential difference in GLP-1RA associated change in brain function, appetite, and eating behaviors.

开始日期2026-05-01

申办/合作机构

University of Colorado Denver

[+1]

NCT06913023

/ Not yet recruiting临床2/3期IIT

Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus

The study aims to determine the short-term efficacy, mechanisms and safety of 24 weeks of placebo and semaglutide therapy in 74 KTR at risk of post-transplant diabetes mellitus (PTDM).

开始日期2026-01-05

申办/合作机构

University Health Network

NCT06977438

/ Not yet recruiting临床4期IIT

Promoting Healthy Children and Youth

The rapid emergence of new and highly effective obesity medications has turned the field of pediatric weight management on its head. Adolescents living with obesity, their caregivers, healthcare providers, healthcare systems, policymakers, and payors are now wondering what role health behavior and lifestyle treatment (HBLT) has in terms of body mass index (BMI) reduction, improvements in quality of life and cardiometabolic health, and mitigating nutritional concerns when medications are used. Is intensive (26+ hours) of HBLT needed or could low intensity HBLT be an equally effective alternative; and if so, for whom? Our proposed project will answer these important questions that arise daily in the clinical setting and will generate critical new insights to guide decision-making for teens with obesity and the stakeholders who care deeply about them.

开始日期2026-01-01

申办/合作机构

University of Minnesota

100 项与司美格鲁肽 (诺和诺德) 相关的临床结果

登录后查看更多信息

100 项与司美格鲁肽 (诺和诺德) 相关的转化医学

登录后查看更多信息

100 项与司美格鲁肽 (诺和诺德) 相关的专利（医药）

登录后查看更多信息

254

项与司美格鲁肽 (诺和诺德) 相关的文献（医药）

2025-12-31·JOURNAL OF MEDICAL ECONOMICS

Impact of semaglutide 2.4 mg on healthcare resource utilization and medical costs in patients with atherosclerotic cardiovascular disease in the United States (SHINE-ASCVD)

Article

作者: Zhao, Zhenxiang ; Alvarez, Sara ; Faurby, Mads ; Michalak, Wojciech ; Fitch, Angela

BACKGROUND:

Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality. Semaglutide 2.4 mg (Wegovy) has demonstrated improved outcomes in patients with overweight or obesity (ov/ob) and ASCVD, but its impact on medical costs and healthcare resource utilization (HCRU) remains unknown.

AIMS:

To compare all-cause medical costs and HCRU among patients with ov/ob and ASCVD treated with semaglutide 2.4 mg versus semaglutide-untreated controls.

MATERIALS AND METHODS:

This observational cohort study utilized Komodo's Healthcare Map and included patients with ov/ob and ≥1 diagnosis of ASCVD during the baseline period with ≥12 months of insurance coverage before and after the index date. Patients in the semaglutide 2.4 mg cohort initiated treatment after 4 June 2021 and stayed adherent. Semaglutide-untreated controls were randomly selected and 1:4 propensity score matched based on baseline demographics, clinical characteristics, medical costs, and HCRU. Medical costs and HCRU were compared using generalized linear models.

RESULTS:

770 semaglutide 2.4 mg-treated patients and 3,080 controls were included. In the year following treatment initiation, semaglutide 2.4 mg was associated with 22% lower mean medical costs versus controls (-$4,639 per patient per year [PPPY]; cost ratio = 0.78, 95% confidence interval [CI] 0.67, 0.89). This difference is mainly due to lower inpatient costs with semaglutide 2.4 mg, which were 65% lower than controls (-$3,593; cost ratio = 0.35 [95% CI 0.21, 0.49]), along with a 48% lower inpatient visit rate (0.08 vs. 0.15; rate ratio = 0.52 [95% CI 0.34, 0.70]).

LIMITATIONS:

Limitations inherent to retrospective claims analyses apply to this study.

CONCLUSIONS:

This real-world analysis shows significantly lower annual medical costs and HCRU with semaglutide 2.4 mg versus no semaglutide 2.4 mg treatment in patients with ov/ob and ASCVD. Improving outcomes with semaglutide 2.4 mg combined with lower costs and HCRU may help slow the growing burden of ASCVD in this population.

2025-12-31·JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness of semaglutide in people with obesity and cardiovascular disease without diabetes

Article

作者: Lübker, Christopher ; Lincoff, A. Michael ; Bøg, Martin ; Lingvay, Ildiko ; McEwan, Phil ; Toliver, Joshua C. ; Yeates, Florian ; Faurby, Mads ; Miller, Ryan ; Foos, Volker

AIMS:

The cardioprotective effects of semaglutide 2.4 mg reported in the SELECT cardiovascular (CV) outcomes trial (ClinicalTrials.gov NCT03574597) provide clinical benefit for subjects with overweight or obesity and established CV disease without type 2 diabetes (T2D). We assessed cost-effectiveness of semaglutide 2.4 mg in this population against the American College of Cardiology/American Heart Association value framework.

MATERIALS AND METHODS:

A cohort-level Markov-state cost-effectiveness model using trial-derived data with outcomes from a healthcare sector perspective measured over a lifetime horizon was developed. Treatment costs were based on US list prices; scenario analyses used literature-reported estimated rebates. Healthcare costs and benefits were discounted at 3.0%. A simulated cohort of 100,000 subjects was aligned to the SELECT trial population baseline characteristics and time-on-treatment. Subjects received either semaglutide 2.4 mg or placebo in addition to standard of care (SoC). Modelled outcomes included clinical events (CV events, progression to T2D, chronic kidney disease [CKD]) and health economic measures, including direct costs and quality-adjusted life years (QALYs).

RESULTS:

Mean semaglutide 2.4 mg treatment duration was 2.79 years. Per 100,000 subjects, treatment avoided 2,791 non-fatal myocardial infarctions, 3,000 coronary revascularizations, 487 non-fatal strokes, and 115 CV deaths over the modeled lifetime horizon. Average per-subject lifetime treatment costs were $47,353; savings arose from avoided T2D ($14,431), CKD ($2,074), and CV events ($1,512). Semaglutide 2.4 mg was associated with increased lifetime costs ($29,767), additional QALYs gained (0.218) and an incremental cost-effectiveness ratio of $136,271/QALY at list price; a scenario using an empirically estimated 48% rebate predicted $32,219/QALY.

LIMITATIONS:

The generalizability of observations from SELECT to a broader US population is unknown. Our model does not capture all outcomes nor costs that may be affected by weight loss. Modeling assumptions may present limitations.

CONCLUSIONS:

Semaglutide 2.4 mg use as in SELECT is cost-effective at list price, using a $150,000/QALY willingness-to-pay threshold.

2025-09-01·Obesity Pillars

Antiemetic effect of acupressure wristbands for GLP-1 medication associated nausea

Article

作者: Reyes, Anita ; Belarj, Soufiane ; Ziemke, Florencia ; Istfan, Nawfal ; Esguerra, Jem

Background:

Nausea is one of the most reported side effect of GLP-1 receptor agonists (GLP-1a). Current recommendations fall short in taming the symptoms, include antiemetic medication, behavior changes, GLP-1a dose adjustment, and often cause a disruption to treatment. Sea-Band® is a drug-free, class II FDA-cleared medical device for relief of nausea in motion sickness, morning sickness, chemotherapy and anesthesia induced nausea. The device is a set of soft, elastic, reusable acupressure wristbands (ACW) with a skin-facing plastic button worn below the wrist crease applying pressure at acupoint pericardium 6. We hypothesized that ACW was an effective tool for GLP-1a associated nausea.

Methods:

This was a one-arm, open-label, non-randomized, prospective interventional study evaluating the antiemetic effect of ACW in non-pregnant adults on GLP-1as with nausea. GLP-1a were semaglutide or tirzepatide. Exclusion criteria were patients on GLP-1a without nausea, recent use of antiemetic medications, other nausea-related conditions, history of gastroparesis, and uncontrolled gastroesophageal reflux disease. Patients were shown how to properly place and use ACW at the onset of nausea and were followed weekly for 4 weeks. Follow-ups assessed frequency of nausea, ACW use frequency and duration, and change in nausea.

Results:

359 episodes of nausea were recorded amongst 31 adult participants over 4 weeks. Adults, mean age 55, mean BMI 34, mean HbA1c 5.9 %, reported nausea over 80 % of the time on a weekly basis. ACW were used in all recorded episodes of nausea. Medication doses were kept stable throughout the duration of this study. Nausea relief was achieved within 5 min in one third of episodes, and in over 5 min but under 20 min in the remainder of the episodes. A logistic regression model was used to evaluate the likelihood of nausea relief. A consistent rate of nausea relief over 80 % was observed during the study period, adjusting for the correlation between reduced nausea episodes and reduced episodes.

Conclusion:

Although not a controlled trial, this pilot, proof of concept, pragmatic study suggests that ACW may offer a safe, self-administered, reusable, and drug-free option for managing GLP-1a associated nausea.ACW's nausea reducing effect was seen in over 80 % of episodes, and remained consistent throughout the study period. One third of participants experienced relief within 5 min of wearing ACW in the first three weeks. Given the relatively small sample size of the population, further large-scale investigations are justified. Nausea is common in day-to-day real-world use of GLP-1as, and our results suggest that using ACW may provide a first-line therapeutic intervention used ad libitum to tame a disruptive symptom, improve day-to-day well-being, and positively impact a person's treatment journey on GLP-1a.

5,399

项与司美格鲁肽 (诺和诺德) 相关的新闻（医药）

2025-07-23

·赛柏蓝

医生 IP 发力，处方药科普事半功倍

在 AIGC、数字人等新技术不断赋能医药行业的当下，医生 IP 已成为处方药科普传播的核心抓手，这背后既有政策的强力驱动，更有实实在在的行业价值。01政策东风：医生 IP 迎来黄金发展期国家层面正持续为健康科普 “铺路”。2023 年 4 月设立的科普奖，将健康科普纳入社会表彰体系；《“健康中国 2030” 规划纲要》更是明确了科普在健康中国建设中的核心地位。部委层面，2019 年起健康指标已纳入地方政府绩效考核，2022 年九部门联合印发的全媒体科普机制文件，要求构建覆盖全渠道的健康知识传播网络。地方实践同样积极。以上海为例，科协定额资助健康科普项目，将科普作品纳入医护人员职称评定；河南、山东等 17 个省份 / 直辖市已明确要求医生每年参与不少于 2 次健康科普活动。医院层面更是动作频频，协和星原计划、东方启明计划等专项科普计划陆续落地，科普大赛成为医院品牌建设的常规动作。这些政策不仅为医生 IP 提供了合规发展的土壤，更让处方药科普有了明确的传播载体 —— 通过医生 IP 输出的专业内容，既能满足政策对科普的要求，又能实现处方药知识的精准触达。02多方共赢：医生 IP 激活科普全链条价值医生 IP 的价值绝非单一维度，而是能同时赋能医生、医院、患者与药企的生态型存在。对医生而言，科普已成为职业发展的 “刚需”。参与科普不仅能完成职称晋升、评优评级的考核指标，更能提升个人品牌知名度。某心血管领域医生通过 IP 运营，年度增粉 16.5 万，单条视频最高传播 450 万次，既加深了医患沟通，也获得了阳光收入（如平台流量奖励、知识付费分成等）。对医院来说，医生 IP 是品牌建设的利器。通过医生群体的科普传播，医院能高效完成国家科普任务，提升公信度与患者粘性。上海某医院心内科团队的科普项目，获得 100 万元专项资助，超额完成推文、视频创作任务，最终跻身上海市新媒体影响力排名第二，患者转诊率提升 35%。对患者而言，医生 IP 是权威信息的 “过滤器”。在信息繁杂的互联网环境中，认证医生输出的处方药科普内容（如用药指南、副作用解读）能帮助患者建立科学认知，从 “被动治疗” 转向 “主动健康管理”。某降糖药企业的医生 IP 矩阵，累计覆盖 230 万患者，用药依从性提升 28%，不良反应咨询量下降 43%。对处方药企业来说，医生 IP 是合规营销的 “桥梁”。通过医生 IP 进行的内容科普，既能规避传统推广的合规风险，又能实现品牌与产品信息的精准渗透。司美格鲁肽通过医生 IP 矩阵传播减肥适应症，借助社交平台快速破圈，成为现象级产品，这正是医生 IP 赋能处方药传播的典型案例。03实战赋能：医生 IP 如何落地处方药科普？在实操层面，医生 IP 为处方药科普提供了多元化的传播路径，结合新技术工具更能实现 “降本增效”。 1. 全平台内容矩阵，覆盖患者全旅程以短视频平台（抖音、快手、视频号）为核心，图文平台（公众号、头条号）为补充，构建全域传播网络。例如某药企孵化的 100 + 医生 IP 矩阵，年度科普传播量达 20 亿人次，通过 “疾病认知 - 用药指导 - 康复管理” 的内容链条，将处方药知识融入患者全诊疗周期。 2. 借势热点营销，放大科普声量结合健康节日、疾病防治日策划专题活动，如 “世界心脏日” 联合 30 + 心内科医生发布《8 个伤 “心” 的习惯》，阅读量超 283 万；“全国爱眼日” 发起 #及早护眼防病变# 话题，联合 1000+KOL/KOC，总阅读量 1.7 亿，推动糖尿病眼病科普深入人心。这种 “热点 + 专业” 的模式，能让处方药科普更具传播力。 3. 技术工具加持，提升创作效率借助 AIGC 与数字人技术，医生 IP 内容创作效率显著提升。例如 “医生 IP 加速器” 可提供爆款选题库、短视频一键生成功能，5 分钟即可完成一条科普视频；数字人医生能无限克隆医生形象，解决临床工作繁忙、拍摄时间不足的痛点。某药企通过数字人医生 IP 矩阵，3 个月累计传播量 650 万 +，大幅降低内容生产成本。 4. 流量转化闭环，从科普到服务通过 “小荷健康” 等平台，医生 IP 可直接挂载出诊信息、挂号入口，实现 “科普 - 咨询 - 诊疗” 的闭环。某肿瘤药企的医生 IP 矩阵，不仅带动相关处方药市场份额从 12% 提升至 21%，更让合作医院的患者复诊率提高 35%，实现了科普价值向临床价值的转化。04医生 IP 是处方药科普的 “长效引擎”当下，处方药科普正从 “单向传播” 转向 “双向互动”，医生 IP 正是这一转变的核心载体。它既能满足政策对健康科普的要求，又能为药企提供合规、高效的传播路径，更能让患者获得权威、易懂的用药知识。赛柏蓝在医生 IP 孵化领域积累了丰富经验，从 IP 定位、内容创作到全平台运营，可提供一站式解决方案。如果您的企业正在寻找处方药科普的新突破口，不妨从打造医生 IP 开始 —— 让专业的人说专业的话，让优质的处方药知识真正触达需要的患者。期待与各位携手，共同探索医生 IP 赋能处方药科普的更多可能，为医药产业的健康发展注入新动能。扫码联系我们，获得您专属策略END*声明：此篇文章受众仅为医药、医疗等健康产业专业伙伴，仅供医学药学专业人士使用，不针对普通消费大众。

高管变更IPO

2025-07-23

·生物制药进展杂评

11.5亿美元前期付款，赛诺菲收购的RSV疫苗公司有何亮点？国内卷王为何不值钱~

2025年7月22日，赛诺菲（Sanofi）今日宣布已达成协议，将收购总部位于英国伦敦的私营生物技术公司Vicebio有限公司（“Vicebio”）。根据协议条款，赛诺菲将以11.5亿美元的前期付款收购Vicebio的全部股本，此外，基于研发，这价值和监管方面的成就，还可能支付高达4.5亿美元的里程碑款项。1.关于首付款,11.5亿美元的前期付款再看看国内出海的产品，虽然满屏都是几十亿美元的交易，但是再看看首付看是不是都是白菜价～昨天科弈药业宣布，与美国生物医药企业ERIGEN LLC达成战略合作，网上都是20亿美元的BD交易，但是近期付款仅有1500万美元。科弈药业将获得1500万美元近期开发里程碑付款，并有资格获得总金额最高达13.2亿美元的研发、注册及商业化阶段里程碑付款，此外，科弈药业还将基于KQ-2003在授权区域的净销售额，获得最高8亿美元的销售分成。简评！超20亿美元，双靶点CAR-T出海的核心看点，附竞争产品列表荣昌生物的泰它西普官宣BD出海，4500万首付款下的41亿总额，略显~~~~~~即使当时普米斯被收购，价格和这个相比也少了不少双抗领域的一些思考，写在普米斯生物被9.5亿美元收购后18亿美元被收购！扒扒普方生物的管线和平台出现这种差异核心还是在产品和技术～也许还有一点中国制造就得便宜的偏见~2、公司的核心技术——Molecular Clamp technology下图是他们自己文献中的图片《Development of molecular clamp stabilized hemagglutininvaccines for Influenza A viruses》，通过图片大概就知道这个技术的核心目的：就是为了维护亚单位疫苗的天然构象，同时也为了方便生产~3、公司核心产品~公司官网的pipeline，刨除新冠，有家的就只有三个，最快的是前两个，都是多价苗，这是一个特色- VXB-241：这是一款针对RSV和hMPV的二价疫苗候选产品，目前正在老年人群体中开展1期探索性研究。- VXB-251：一款处于临床前阶段的三价疫苗候选产品，目标是针对RSV、hMPV（人类偏肺病毒）以及3型副流感病毒（PIV3）。RSV、hMPV和PIV3是导致肺炎等下呼吸道感染的主要原因。4、国内RSV 疫苗，卷死不偿命国内RSV疫苗领域本来一直也不愠不火，直到mRNA 大潮来袭，后新冠时代，RSV也成为mRNA 内卷的主战场，截止目前国内以后超过40多个RSV疫苗，进入临床阶段有30个产品，mRNA疫苗有15款，一半左右。这15家mRNA疫苗估计现在都跳不出特点（亮点）。其他重组的又有多少特色呢？（没有具体去看各家的特色，欢迎留言讨论）这么多产品卷下来，恐怕都难言成功司美格鲁肽和8201光芒下，罗氏新三驾马车和RSV三国争市场的惊喜数据RSV疫苗和长效预防性抗体，既生瑜何生亮？新冠后，RSV已成为呼吸道传染疾病领域下一个主战场回到这个交易，面对这么多可选产品，赛诺菲也没有来国内扫货~大概也可以说明一些事情不过很快，国内企业在RSV这个领域的竞争，就会有了新的方向——多价苗。都是大聪明，很容易的~除了hMPV，别的选什么？拭目以待。RSV和流感如果也可以搞一起，会更有市场不过因为流感病毒株总在变做起来有难度～总之～国内的医药BD还是秉承了制造业低价的传统。反内卷，不只是煤炭、光伏，疫苗也可以的~

疫苗并购临床1期免疫疗法细胞疗法

2025-07-23

·BioSpace

GLP-1s Could Protect Against Neurodegeneration, Study Finds

iStock, BeritK A retrospective cohort study found that semaglutide and tirzepatide are linked with significantly lower risks of dementia and stroke, hinting at potential neuroprotective effects of GLP-1 therapies. Novo Nordisk’s semaglutide and Eli Lilly’s tirzepatide—both leading GLP-1 agonists used for weight loss and diabetes—are associated with a lowered likelihood of developing neurodegenerative disorders such as dementia, according to a recent study. The retrospective cohort study, published last week in JAMA Network Open , looked at electronic health record data of more than 60,800 adults 40 years and above with type 2 diabetes and obesity who had initiated treatment with semaglutide, tirzepatide or other antidiabetic drugs. Patients with prior neurodegenerative or cerebrovascular conditions were excluded from the analysis. Over seven years of follow-up, patients treated with GLP-1 analogs were 37% less likely to develop dementia than counterparts on other antidiabetic medications. This effect was statistically significant. Aside from dementia, the risks of ischemic stroke and all-cause mortality were likewise significantly reduced in patients treated with GLP-1s, with effect sizes of 19% and 30%, respectively. In contrast, GLP-1 therapies were not associated with altered risk of Parkinson’s disease, mild cognitive impairment and intracerebral hemorrhage versus other antidiabetic agents. These findings carry the usual caveats of a cohort study, namely that it could carry “residual confounding from unmeasured factors,” according to the paper’s authors, such as the patients’ functional status and frailty. The database that the study drew from also does not have biomarker and genetic data or neuroimaging information, leaving a mechanistic blind spot for its results. Still, these findings point to the “potential neuroprotective and cerebrovascular benefits” of GLP-1 drugs, according to the researchers, who added that future randomized trials in these patient populations are needed to “validate our findings and establish causality.” Novo is already working toward that end. The Danish pharma is running the Phase III EVOKE and EVOKE Plus studies to test semaglutide in Alzheimer’s disease. Both studies have a primary completion date in September 2025. Novo has also previously tested its older-generation GLP-1 therapy liraglutide in a Phase IIb study and found that treated patients saw 18% slower cognitive decline than those on placebo. For Lilly, the neuroprotective effects of tirzepatide could make the obesity drug a good complement to Kisunla, an anti-amyloid antibody approved in July 2024 for Alzheimer’s disease. The pharma is currently running the Phase III TRAILBLAZER ALZ-3 trial to test Kisunla in patients with preclinical disease. In a July 22 note to investors, analysts at BMO Capital Markets said that the trial could read out sooner than expected, “potentially by the start of 4Q25.” Additionally, even an interim analysis could be sufficient to detect statistical significance on disease progression. In such a case, analysts added, data from TRAILBLAZER ALZ-3 “could illustrate the value of treating presymptomatic patients with beta-amyloid therapies.”

临床2期临床3期上市批准临床结果

100 项与司美格鲁肽 (诺和诺德) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10025	司美格鲁肽 (诺和诺德)	A10BJ06	DB13928

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
慢性肾病	美国	Novo Nordisk A/S	2025-01-28
慢性肾病	美国	Novo Nordisk, Inc.	2025-01-28
脑卒中	澳大利亚	Novo Nordisk Pharmaceuticals Pty Ltd.	2024-12-16
心肌梗塞	加拿大	Novo Nordisk Canada, Inc.	2024-11-27
肥胖	美国	Novo Nordisk, Inc.	2021-06-04
超重	美国	Novo Nordisk, Inc.	2021-06-04
2型糖尿病	美国	Novo Nordisk, Inc.	2017-12-05

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
非酒精性脂肪性肝炎	申请上市	美国	Novo Nordisk A/S	2025-04-30
白蛋白尿	临床3期	加拿大	Novo Nordisk A/S	2022-03-14
白蛋白尿	临床3期	德国	Novo Nordisk A/S	2022-03-14
白蛋白尿	临床3期	荷兰	Novo Nordisk A/S	2022-03-14
白蛋白尿	临床3期	西班牙	Novo Nordisk A/S	2022-03-14
膝关节炎	临床3期	美国	Novo Nordisk A/S	2021-10-01
膝关节炎	临床3期	加拿大	Novo Nordisk A/S	2021-10-01
膝关节炎	临床3期	哥伦比亚	Novo Nordisk A/S	2021-10-01
膝关节炎	临床3期	丹麦	Novo Nordisk A/S	2021-10-01
膝关节炎	临床3期	法国	Novo Nordisk A/S	2021-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03574597 (SELECT, Pubmed \| J Med Econ)	临床3期	心血管疾病 \| 肥胖	-	Semaglutide 2.4 mg	觸觸觸鑰襯艱觸糧襯築(艱糧構願壓構淵窪製鬱) = 鏇願願繭積鹽蓋製蓋壓遞積淵鏇鏇鑰淵窪夢鏇 (夢壓獵遞憲製網憲繭膚 ) 更多	积极	2025-12-31
NCT05530577 (CTgov)	临床2期	尼古丁依赖	24	Semaglutide (Semaglutide)	簾獵憲艱鬱簾積醖衊窪(鏇獵餘壓觸簾艱遞繭觸) = 蓋夢觸壓鹽遞壓簾蓋鹽衊糧齋積廠糧觸範廠選 (鏇鏇觸觸製鹹鑰鑰醖獵, 0.63) 更多	-	2025-07-18
				Sham/placebo (Sham/Placebo)	簾獵憲艱鬱簾積醖衊窪(鏇獵餘壓觸簾艱遞繭觸) = 醖窪積窪簾糧襯範衊範衊糧齋積廠糧觸範廠選 (鏇鏇觸觸製鹹鑰鑰醖獵, 0.69) 更多
NCT04560998 (STRIDE, CTgov)	临床3期	2型糖尿病 \| 外周动脉疾病	792	Semaglutide	夢範齋鬱顧鹹範鹹餘鬱(衊簾艱夢蓋膚膚鏇齋鏇) = 積餘網艱窪齋淵繭鏇獵衊願壓簾窪繭鬱鏇製鹽 (鬱網遞觸鏇繭齋鬱簾淵, 獵鬱鑰憲繭衊餘構醖觸 ~ 鬱糧蓋網獵衊壓廠鹹餘) 更多	-	2025-07-08
ACTRN12621001539820 (Pubmed) 人工标引	临床2期	-	31	Semaglutide	餘顧選壓繭廠獵顧繭範(夢製獵齋艱網顧繭選簾) = 顧醖襯夢壓積膚鹹襯餘壓膚膚積鹹築簾構鑰憲 (網艱廠願選築願餘簾遞, 0.90)	积极	2025-07-01
				placebo	餘顧選壓繭廠獵顧繭範(夢製獵齋艱網顧繭選簾) = 齋積膚繭衊選獵願範艱壓膚膚積鹹築簾構鑰憲 (網艱廠願選築願餘簾遞, 0.93)
NCT06282458 (QUALITY, GlobeNewswire) 人工标引	临床2期	肌肉萎缩 \| 肥胖	148	Placebosemaglutide (after discontinuation of semaglutide; Day 112 to Day 196, ITT population)	糧艱窪鹹願襯積窪鬱餘(艱築鑰廠觸壓鹽膚糧範) = 夢鏇衊憲蓋鹽網鏇繭艱鹽積鹽願餘鏇遞夢構獵 (製顧襯簾鬱衊艱鹹構觸, 0.40) 更多	积极	2025-06-24
				Enobosarm 3mgsemaglutide (after discontinuation of semaglutide; Day 112 to Day 196, ITT population)	糧艱窪鹹願襯積窪鬱餘(艱築鑰廠觸壓鹽膚糧範) = 憲窪觸醖憲夢壓蓋獵獵鹽積鹽願餘鏇遞夢構獵 (製顧襯簾鬱衊艱鹹構觸, 0.40) 更多
BELIEVE (NEWS) 人工标引	临床2期	超重 \| 肥胖	507	Bimagrumab/Semaglutide	醖遞襯構醖窪衊構膚範(淵選鹹壓廠窪範衊齋餘) = 繭簾選壓製襯餘餘築繭衊夢膚膚鹽壓製構築製 (繭糧鏇鹹築觸鬱築繭蓋 ) 更多	积极	2025-06-23
				Bimagrumab	醖遞襯構醖窪衊構膚範(淵選鹹壓廠窪範衊齋餘) = 鹹襯築糧獵餘窪構鏇選衊夢膚膚鹽壓製構築製 (繭糧鏇鹹築觸鬱築繭蓋 ) 更多
NCT05537233 (ADJUST-T1D, Pubmed \| NEJM Evid)	临床2期	1型糖尿病 \| 肥胖	72	Semaglutide up to 1 mg	鏇簾艱築膚簾廠齋憲繭(觸獵糧獵鑰襯艱築鏇製) = 衊範範鏇艱衊襯醖蓋夢憲築鑰遞齋構願獵觸艱 (淵餘積夢憲築獵獵築遞, -10.6 ~ -7.0) 更多	积极	2025-06-23
				Placebo	-
NCT05646706 (STEP UP, ADA2025 \| NEWS) 人工标引	N/A	肥胖	1,407	semaglutide 7.2mg	鏇廠窪獵築襯鏇鹽鏇鹽(遞糧積築餘鑰窪醖網鑰) = 選壓醖憲鑰鏇鑰醖繭鹽蓋鏇廠窪夢壓鑰壓淵範 (鹽襯糧製餘製鹹觸醖憲 ) 更多	积极	2025-06-20
				semaglutide 2.4mg	鏇廠窪獵築襯鏇鹽鏇鹽(遞糧積築餘鑰窪醖網鑰) = 觸夢鹹淵壓鬱壓醖遞製蓋鏇廠窪夢壓鑰壓淵範 (鹽襯糧製餘製鹹觸醖憲 ) 更多
NEWS 人工标引	N/A	肥胖	-	Semaglutide/Tirzepatide	餘淵淵憲襯醖憲壓窪憲(遞廠壓鏇淵窪淵鹹顧構) = 構鬱壓鹹簾廠齋憲壓醖糧顧構構膚範鹹鬱艱網 (鹹膚醖積觸蓋齋簾壓蓋 ) 更多	-	2025-06-10
NCT04822181 (Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis, Pubmed \| N Engl J Med)	临床3期	非酒精性脂肪性肝炎	1,197	Semaglutide 2.4 mg	鹹範壓築糧壓鹹餘顧襯(窪壓齋鑰製鬱壓獵鬱衊) = 選糧製膚廠選醖鹹積夢鹽蓋壓鬱簾顧衊廠構觸 (膚襯齋鹽衊觸願獵構鬱, 7.5 ~ 21.3) 更多	积极	2025-06-05
				Placebo	鹹範壓築糧壓鹹餘顧襯(窪壓齋鑰製鬱壓獵鬱衊) = 願鏇艱簾獵醖鹽餘築繭鹽蓋壓鬱簾顧衊廠構觸 (膚襯齋鹽衊觸願獵構鬱 ) 更多